Price movement over the last 24 hours
Agilent Technologies Inc vs T Rowe Price Group Inc — how do they compare? Agilent Technologies Inc trades at $128.78 (market cap $37.04B), while T Rowe Price Group Inc trades at $117.35 (market cap $25.75B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| A | TROW | |
|---|---|---|
Market Cap | $37.04B | $25.75B |
Sector | Health | Financials |
52-Week High | $157.20 | $120.16 |
52-Week Low | $110.24 | $86.19 |
Enterprise Value | $38.59B | $22.45B |
Dividend Yield | 0.78% | 4.33% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
T. Rowe Price (TROW) trades at $120.16, up 1.36% with bullish technical indicators showing strong momentum above key support levels. The company maintains solid fundamentals with $7.31B revenue, 28.28% net margin, and attractive valuation at 12.78 P/E. Recent earnings beat expectations in Q1 2026, while strategic initiatives in institutional services and AI-focused content demonstrate proactive positioning.
TROW presents a mixed outlook with strong profitability and cash flow generation offset by analyst caution. The stock trades above consensus target ($101.57) but offers dividend appeal with recent $1.30 payout. Key risks include equity outflows and market sensitivity, while institutional enhancements and debt-free balance sheet provide stability.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →